Two-dose COVID-19 vaccines could complicate efforts to immunize billions of people

A COVID-19 vaccine that requires two doses may be more effective at protecting against the disease, but would also make the effort to immunize billions of people much more complicated, Bloomberg reported. 

AstraZeneca, in partnership with the University of Oxford in England, and Moderna are planning to conduct final-stage testing of vaccines that would require two doses. Almost all standard vaccines are multiple-shot regimens, Tony Moody, MD, an immunologist at the Duke Human Vaccine Institute, told Bloomberg

But the need for two doses would make manufacturing and logistics more complex. 

"A one-shot vaccine would be ideal, but the first vaccines are highly unlikely to meet this very high threshold," Michael Kinch, PhD, a vaccine specialist and associate vice chancellor at Washington University in St. Louis, told Bloomberg. "As we hopefully move from whether there will be a vaccine to how to apply this, logistics are going to become the absolute most important topic."

Because a two-shot vaccine will be harder to distribute, it will likely disadvantage developing countries, Bloomberg reported. The challenges would multiply if the vaccine's efficacy wanes over time and repeat doses are needed, such as with the flu shot. 

Merck has committed to only pursuing one-dose vaccines to simplify worldwide distribution, but its vaccine has yet to enter human trials. 

Read the full article here.

More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers